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 Introduction 
The purpose of this monograph is to provide information on drug retention times in the 
human body.  The information provided is based on plausible illegal drug use activities that 
might be engaged in by a recreational drug user. 
 
Based on anecdotal evidence, most people “party” during extended time away from the work 
environment.  Therefore, the following scenarios were envisioned: (1) a person uses an illicit 
drug at a party on Saturday night (infrequent user); (2) a person uses a drug one time on 
Friday night and once again on Saturday night (infrequent user); and (3) a person uses a drug 
on Friday night, uses a drug twice on Saturday night, and once again on Sunday (frequent 
user).  
Drugs 
The categories of drugs considered, collectively known as the SAMHSA 5,∗ are: 
• marijuana (and metabolites) 
• cocaine (and metabolite) 
• opiates (and metabolites) 
o heroin (and metabolites) 
o morphine (and metabolites) 
o codeine (and metabolites) 
• amphetamines 
o amphetamine 
o methamphetamine 
• phencyclidine (PCP) (and metabolite) 
 
Table 1 identifies the drugs in the SAMHSA 5 including the total number of metabolites and 
the major metabolite(s) corresponding to each drug type.  A drug’s metabolite is the 
compound produced when the body processes a particular drug.  Identifying these 
compounds is the focus of workplace drug testing analysis.  Marijuana possesses the greatest 
total number of detectable metabolites at 31 but fewer major components.  For 
amphetamines, no metabolites are identified because these substances normally pass through 
the body essentially unchanged in chemical structure. 
                                            
∗ The name is taken from the five categories of drugs included in the U. S. Department of Health and Human 
Services (HHS) guidance on drug testing in the workplace, Substance Abuse and Mental Health Services 
Administration (SAMHSA). 
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Table 1. Drugs and major metabolites 
Drug 
(SAMHSA 5) 
Total number of 
metabolites* 
Major metabolite(s) 1, ** 
Marijuana metabolites 31 11-Nor-delta-9-tetrahydrocannabinol 
(THC) 9 carboxylic acid 
11-Hydroxy-delta-9-tetrahydrocannabinol 
11-Nor-delta-8-tetrahydrocannabinol 
(THC) 9 carboxylic acid 
Cocaine metabolite 4 Benzoylecgonine 
Opiates/metabolites: 3  
Heroin metabolites  6-Acetylmorphine or 
6-Monoacetylmorphine 
Morphine metabolites  Morphine-3-beta-d-glucuronide 
Morphine-6-glucuronide 
Codeine metabolites  Codeine-6-glucuronide 
Morphine-3-glucuronide 
Morphine-6-glucuronide 
Amphetamines:      
Amphetamine  Unchanged amphetamine 
Methamphetamine  Unchanged methamphetamine 
Phencyclidine (PCP) 1 Hydroxylated PCP 
Note:  Throughout the text, superscripts designate references; symbols refer to website links. 
* http://www.passitkit.com/testing1.htm (7/13/06) 
**http://www.keystosaferschools.com/drug_testing_specifics.htm (7/13/06) 
 
Table 2 presents information on detection cutoff levels for the five classes of drugs, both 
initial and confirmatory levels, which are established by the U.S. Department of Health and 
Human Services (HHS).  The drug cutoff level is the lowest concentration (least amount per 
unit volume) of a particular drug or its resulting metabolite(s) remaining in the body that will 
cause a person to be identified as using that substance in a workplace drug test.  The initial 
test refers to the screening assay on specimens to eliminate a “negative” result from the need 
for further analysis.  
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Table 2. Drug detection periods for schedule drugs 1, 2 
Drug 
(SAMHSA 5) 
Route of 
administration 
HHS detection  
cutoff level (ng/ml)* 
Marijuana/metabolites oral, smoked         50 (initial) 
        15 (confirm) 
Cocaine/metabolites injected, smoked, 
snorted 
        150 (initial) 
        100 (confirm) 
Opiates/metabolites:      
Heroin/metabolites injected, smoked, 
snorted 
        2000 (initial) 
        10 (confirm) 
   
Morphine/metabolites injected, oral, 
smoked, snorted 
        2000 (initial) 
        2000 (confirm) 
   
Codeine/metabolites injected, oral         2000 (initial) 
        2000 (confirm) 
Amphetamines:     
Amphetamine injected, oral, 
smoked, snorted 
        500 (initial) 
        250 (confirm) 
   
Methamphetamine injected, oral, 
smoked, snorted 
        500 (initial) 
        250 (confirm) 
Phencyclidine (PCP) injected, oral, 
smoked, snorted 
        25 (initial) 
        25 (confirm) 
*Cutoff levels are expressed in ng/ml, nanogram per milliliter. 
 
Any “positive” screening test result dictates a specimen being subjected to additional analysis 
using a gas chromatograph/mass spectrometry system.  Confirmatory detection cutoff levels 
are more stringent than the initial screening levels (Table 2).  Specimen analysis is done in 
certified laboratories that meet the protocol guidelines and analytical methods and standards 
published by HHS. 
 
An extensive search was conducted of the published literature related to drug retention times 
in the human body and detection requirements.  Major data sources included HHS, 
SAMHSA, and the National Institute on Drug Abuse (NIDA).  However, data containing 
the level of detail required for analysis of the three study scenarios was not available.  Even 
though detailed data were not available, sufficient information was found that allowed an 
analysis that considered “infrequent” or occasional drug use versus “frequent” drug use for 
the SAMHSA 5. 
 
Table 3 provides the detection time periods for the five drugs and their metabolites.  
Additional information is provided on drug detection times, based on whether the individual 
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 is a frequent or infrequent user.  Each detection period is given in a range of days based on 
the best information available from the literature review. 
 
Table 3. Detection periods for Scenarios 1, 2, and 3 
Drug 
(SAMHSA 5) 
Infrequent Use 
Detection period 
(days) 
(Scenarios 1 and 2) 
Frequent use 
Detection period 
(days) 
(Scenario 3) 
Marijuana/metabolites 1 – 5              1 – 35 3, 4, 5 
Cocaine/metabolites 1 − 2 1 – 4 
Opiates/metabolites:   
Heroin/metabolites 1 1 – 2 
Morphine/metabolites 1 – 2 1 – 4 
Codeine/metabolites 1 − 2 1 – 2 
Amphetamines    
Amphetamine  1 – 2 2 – 4 
Methamphetamine  1 – 2 2 – 4 
Phencyclidine (PCP) 2 − 8 7 – 14 
 
Three weekend drug use scenarios were envisioned: (1) a person uses an illicit drug at a party 
on Saturday night (infrequent user); (2) a person uses a drug one time on Friday night and 
once again on Saturday night (infrequent user); and (3) a person uses a drug on Friday night, 
uses a drug twice on Saturday night, and once again on Sunday (frequent user).  With respect 
to the three scenarios outlined, a person using an illegal drug once or twice over a weekend 
was considered an infrequent user, whereas the person using an illegal substance more than 
that over a weekend was considered to be a frequent user.  Table 3 presents effective time 
periods for detecting the SAMHSA 5 drugs by testing infrequent/occasional users and 
frequent users.  The worker using drugs more than twice during a weekend could be tested 
at the far end of the infrequent detection time periods or at the near end of the frequent 
testing time intervals in Table 3.  Users referred to in the literature as chronic, non-
recreational users of these substances would form the bulk of those in our frequent user 
category.  These individuals could be tested with confidence at time intervals toward the far 
end of the frequent use time periods. 
 
Table 3 presents two testing time periods: one for Scenarios 1 and 2 (infrequent use) and the 
other for Scenario 3 (frequent use) of the SAMHSA 5. Testing for marijuana can be 
conducted within five days of infrequent use.  For frequent use, review of the literature3, 4, 5 
indicates that testing for marijuana can be done within eight days, eight days being the half-
life of major marijuana metabolites, and could extend out to as many as 35 days for frequent 
or chronic use.  For cocaine and metabolites, the time interval is one to two days for 
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 Scenarios 1 and 2; for Scenario 3, it is one to four days.  For heroin, the major street opiate, 
testing should be done within one day after infrequent use as in Scenarios 1 and 2 and one to 
two days after frequent use in Scenario 3.  Heroin and its metabolites are typically not 
retained in the body more than one day for those who can limit their use.  Testing for 
morphine requires one to two days for Scenarios 1 and 2 and one to four days for 
Scenario 3.  In the case of codeine, the detection period is one or two days for all scenarios.  
Since the window for testing is one to two days for infrequent use of opiates, testing more 
frequently will increase the potential for detecting opiates.  Amphetamines, including 
amphetamine and methamphetamine, would both require drug testing to be done within 
time intervals of one to two days for Scenarios 1 and 2 and two to four days for Scenario 3.  
Phencyclidine detection periods are two to eight days for Scenarios 1 and 2 and seven to 14 
days for Scenario 3. 
Findings 
The effective detection periods show that a “Saturday night only” user (Scenario 1) would 
likely be identified in a drug test conducted the following Monday, with the possible 
exception of heroin and its metabolites.  Effective detection of marijuana and phencyclidine 
could be accomplished during a longer detection period.  A Friday and Saturday night user 
(Scenario 2) could be identifiable the following Monday at the latest except for heroin and its 
metabolites.  If a drug test were conducted later, for example, on Wednesday or Thursday of 
the week following Friday and Saturday use, marijuana or phencyclidine are the only drugs 
that would likely be detected.  It is possible that even regular users of marijuana may not be 
identified during routine testing after Thursday of a given week following use the pervious 
weekend.  In the case of using a drug four times over the weekend (Scenario 3), all drug 
types would be detectable through the following Thursday except heroin and codeine, which 
would require testing by Monday and Tuesday, respectively.  Due to longer retention times, 
the drugs (and metabolites) that would likely be detected for frequent users are marijuana 
and phencyclidine.  Marijuana and phencyclidine could be detected for longer periods of 
time from eight days for phencyclidine to several weeks for marijuana as shown in Table 3. 
Conclusions 
The following general conclusions can be drawn from the findings in this report: 
• In general, to identify recreational (infrequent) users, conduct drug testing early in 
the work cycle, occasionally testing later in the work cycle to minimize predictability 
of the random tests.  This assumes drug use only during the weekend time period.  
Use of drugs during the week would shift the detection time frame. 
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 • Because of the short detection period, it would be difficult to identify recreational 
opiate use by random testing protocols if the individual is capable of avoiding the 
strong addictive tendency and use it infrequently during non-working periods of at 
least two days.  Although codeine is somewhat less addictive than heroin, the same 
would apply to this substance. 
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